Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration.

IF 2 4区 医学 Q2 OPHTHALMOLOGY
Ophthalmic Research Pub Date : 2024-01-01 Epub Date: 2024-09-05 DOI:10.1159/000540194
Lisa Toto, Federico Formenti, Maria Ludovica Ruggeri, Alberto Quarta, Anna Romano, Chiara De Nicola, Luca Belloni Baroni, Annamaria Porreca, Marta Di Nicola, Rodolfo Mastropasqua
{"title":"Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration.","authors":"Lisa Toto, Federico Formenti, Maria Ludovica Ruggeri, Alberto Quarta, Anna Romano, Chiara De Nicola, Luca Belloni Baroni, Annamaria Porreca, Marta Di Nicola, Rodolfo Mastropasqua","doi":"10.1159/000540194","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to evaluate functional and anatomical changes in patients with neovascular age-related macular degeneration (nAMD) treated with a loading dose of faricimab intravitreal injections (IVIs).</p><p><strong>Methods: </strong>Eighteen eyes of 18 patients with active macular neovascularization and nAMD were enrolled at the Ophthalmology Clinic of University G. D'Annunzio, Chieti-Pescara, Italy. All patients were scheduled for faricimab IVI as per label. Enrolled patients underwent complete ophthalmic evaluation, including optical coherence tomography, fluorescein angiography, and indocyanine green angiography. All measurements were evaluated at baseline (T0) and then monthly up to week 20 (T4). Main outcome measures were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), pigment epithelial detachments (PEDs) presence and maximum height (PED-MH), intraretinal fluid (IRF) presence, subfoveal subretinal fluid (SSRF) presence and thickness.</p><p><strong>Results: </strong>BCVA improved and CMT reduced significantly during follow-up (p &lt; 0.001). In addition, SFCT decreased significantly (p = 0.031). Between T0 and T4, SSRF presence reduced from 55.6 to 16.7% (p = 0.045); IRF presence changed from 50 to 22.2%, respectively (p = 0.074). PED-MH was reduced in 58.8% of patients at T4. At week 20, 72.3% of patients were in the q12/q16 interval.</p><p><strong>Conclusion: </strong>Faricimab showed efficacy in the treatment of naïve nAMD patients with an improvement of anatomical and functional parameters and a treatment interval after the loading phase equal or greater than 12 weeks in the majority of patients.</p>","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540194","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The aim of the study was to evaluate functional and anatomical changes in patients with neovascular age-related macular degeneration (nAMD) treated with a loading dose of faricimab intravitreal injections (IVIs).

Methods: Eighteen eyes of 18 patients with active macular neovascularization and nAMD were enrolled at the Ophthalmology Clinic of University G. D'Annunzio, Chieti-Pescara, Italy. All patients were scheduled for faricimab IVI as per label. Enrolled patients underwent complete ophthalmic evaluation, including optical coherence tomography, fluorescein angiography, and indocyanine green angiography. All measurements were evaluated at baseline (T0) and then monthly up to week 20 (T4). Main outcome measures were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), pigment epithelial detachments (PEDs) presence and maximum height (PED-MH), intraretinal fluid (IRF) presence, subfoveal subretinal fluid (SSRF) presence and thickness.

Results: BCVA improved and CMT reduced significantly during follow-up (p < 0.001). In addition, SFCT decreased significantly (p = 0.031). Between T0 and T4, SSRF presence reduced from 55.6 to 16.7% (p = 0.045); IRF presence changed from 50 to 22.2%, respectively (p = 0.074). PED-MH was reduced in 58.8% of patients at T4. At week 20, 72.3% of patients were in the q12/q16 interval.

Conclusion: Faricimab showed efficacy in the treatment of naïve nAMD patients with an improvement of anatomical and functional parameters and a treatment interval after the loading phase equal or greater than 12 weeks in the majority of patients.

法瑞西单抗对新生血管性老年性黄斑变性患者的疗效和持久性。
引言方法:意大利基耶蒂-佩斯卡拉 G. D'Annunzio 大学眼科诊所招募了 18 名活动性黄斑新生血管 (MNV) 和 nAMD 患者的 18 只眼睛。所有患者均按计划接受法尼单抗静脉滴注。入组患者接受了全面的眼科评估,包括光学相干断层扫描(OCT)、荧光素血管造影和吲哚青绿血管造影。所有测量均在基线期(T0)进行,然后每月进行一次,直至第 20 周(T4)。主要结果指标为最佳矫正视力(BCVA)、黄斑中心厚度(CMT)、黄斑下脉络膜厚度(SFCT)、色素上皮脱离(PEDs)的存在和最大高度(PED-MH)、视网膜内积液(IRF)的存在、视网膜下积液(SSRF)的存在和厚度(SSRFT)的变化:结果:随访期间 BCVA 明显改善,CMT 明显减少(p<0.001)。此外,SFCT 明显下降(p=0.031)。在 T0 和 T4 之间,SSRF 从 55.6% 降至 16.7% (p=0.045);IRF 分别从 50% 降至 22.2% (p=0.074)。58.8%的患者在T4期的PED-MH减少。第20周时,72.3%的患者处于q12/q16区间:结论:法利西单抗对治疗新发 nAMD 患者有疗效,大多数患者的解剖和功能参数得到改善,负荷阶段后的治疗间隔等于或大于 12 周。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmic Research
Ophthalmic Research 医学-眼科学
CiteScore
3.80
自引率
4.80%
发文量
75
审稿时长
6-12 weeks
期刊介绍: ''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信